Literature DB >> 19445268

[Measles].

Ingo Stock1.   

Abstract

Measles are a systemic infectious disease caused by a single stranded ribonucleic acid virus (measles virus) from the paramyxovirus family. Typically, the disease is characterized by a two-phase course. After an average incubation period of 8 to 11 days, initial symptoms such as fever, cough, coryza and conjunctivitis appear. Two thirds of the patients shows a white-marked enanthema on the buccal mucosa (Koplik's spots). After disappearance of these symptoms, a second increase of temperature and the typical measles exanthema, a brownish-red maculopapular rash, appear. Infection with measles virus induces transient immunodeficiency that favours the formation of several complications. Some of them, e. g. encephalitic diseases, are severe and associated with a high mortality. Measles are world-wide distributed and belong to the ten most frequent infectious diseases in some less developed countries. The disease is associated with a high mortality in some African and South-East Asian countries, in particular in children aged less than 12 months. Of particular note, measles are the most important cause of blindness in children in population with borderline vitamin A status. In Germany, the number of reported measles cases has been declined dramatically since the introduction of a vaccine more than four decades ago. However, regional outbreaks or small epidemics still occur. Because there is no specific antiviral treatment, therapy of measles is symptomatic and depends on the manifestation of the disease. The most important prevention strategy is immunization with a life-attenuated vaccine that can be applied as monovaccination or in combination with mumps and rubella virus (MMR vaccination) or mumps, rubella and varicella virus (MMRV vaccination).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445268

Source DB:  PubMed          Journal:  Med Monatsschr Pharm        ISSN: 0342-9601


  1 in total

1.  Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.

Authors:  Qiaoli Li; Zhenhuan Zhao; Dihan Zhou; Yaoqing Chen; Wei Hong; Luyang Cao; Jingyi Yang; Yan Zhang; Wei Shi; Zhijian Cao; Yingliang Wu; Huimin Yan; Wenxin Li
Journal:  Peptides       Date:  2011-05-19       Impact factor: 3.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.